Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database

被引:17
|
作者
Clinard, F
Sgro, C
Bardou, M
Hillon, P
Dumas, M
Kreft-Jais, C
Escousse, A
Bonithon-Kopp, C
机构
[1] Fac Med & Pharm Dijon, GEREPT Ctr Epidemiol Populat Bourgogne, F-21079 Dijon, France
[2] CHU Dijon, Dept Pharmacol, Dijon, France
[3] CHU Dijon, Ctr Reg Pharmacovigilance, Dijon, France
[4] Agence Francaise Secur Sanitaire Prod Sante, Unite Pharmacovigilance, Paris, France
[5] Fac Med, Lab Biochim Toxicol, Dijon, France
关键词
NSAIDs; adverse drug reaction; Pharmacovigilance;
D O I
10.1007/s00228-004-0761-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims. To examine whether the risk of some selected adverse effects increases with the number of systemic non-steroidal anti-inflammatory (NSAID) drugs. Methods. The French Pharmacovigilance database was examined for an association between drug reaction reports and the exposure to one and two or more NSAIDs using a case/non-case study design. In the analysis, 54,583 spontaneous reports of adverse drug reactions were included, consisting of 2270 reports of hepatic injury, 994 reports of acute renal failure, 194 reports of gastrointestinal bleeding and 525 reports of angioedema, among others. Results. Use of NSAIDs significantly increased the risk of hepatic injury, gastrointestinal bleeding, acute renal failure and angioedema. The odds ratios tended to increase with the number of NSAIDs for hepatic injury, gastrointestinal bleeding and acute renal failure but not for angioedema. In comparison with reports that did not mention any use of NSAIDs, the odds ratios associated with the use of a single NSAID and two or more NSAIDs were respectively 1.2 (95%CI: 0.9-1.5) and 2.2 (95%CI: 1.3-3.8) for hepatic injury, 7.3 (95%CI: 4.9-10.9) and 10.7 (95%CI: 2.9-40.2) for gastrointestinal bleeding, 3.2 (95%CI: 2.5-4.1) and 4.8 (95%CI: 2.6-8.8) for acute renal failure. For angioedema, the odds ratios were roughly similar when a single NSAID (OR=2.7; 95% CI: 2.2-3.4) or two or more NSAIDs (OR=2.0; 95%CI: 0.7-6.0) were used. The risk of severe ADRs (hepatic injury and acute renal failure) was six- to sevenfold higher in reports mentioning concomitant use of two NSAIDs or more than in those that did not. Conclusion. This study shows that concomitant use of two or more NSAIDs was associated with an excess risk of adverse effects such as hepatic injury, acute renal failure and gastrointestinal bleeding. Although simultaneous use of several systemic NSAIDs has no pharmacological justification, this may raise a serious public health problem with the increasing use of over-the-counter non-steroidal anti-inflammatory agents.
引用
收藏
页码:279 / 283
页数:5
相关论文
共 33 条
  • [1] Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database
    François Clinard
    Catherine Sgro
    Marc Bardou
    Patrick Hillon
    Monique Dumas
    Carmen Kreft-Jais
    André Escousse
    Claire Bonithon-Kopp
    European Journal of Clinical Pharmacology, 2004, 60 : 279 - 283
  • [2] Drug-induced dementia:: a case/non-case study in the french pharmacovigilance database
    Favreliere, S.
    Brunet, G.
    Saulnier, P. J.
    Merlet, I.
    Alkhidir, F.
    Perault-Pochat, M. C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 68 - 68
  • [3] Drug-induced dementia:: A case/non-case study in the French pharmacovigilance database
    Favreliere, Sylvie
    Lafay-Chebassier, Claire
    Alkhidir, Fuad
    Merlet, Isabelle
    Pochat, Marie-Christine Perault
    THERAPIE, 2007, 62 (06): : 507 - 511
  • [4] Drug-induced hyperprolactinaemia: A case/non-case study in the French pharmacovigilance database
    Petit, A
    Piednoir, D
    Germain, ML
    Trenque, T
    THERAPIE, 2003, 58 (02): : 159 - 163
  • [5] Drug hypersensitivity: a case/non-case study from a Tunisian pharmacovigilance database
    Chaabane, A.
    Ben Fadhl, N.
    Chadli, Z.
    Ben Fredj, N.
    Boughattas, N. A.
    Aouam, K.
    ALLERGY, 2013, 68 : 389 - 389
  • [6] Drug-induced hearing loss: a case/non-case study in the French pharmacovigilance database
    Favreliere, Sylvie
    Delaunay, Paul
    Lebreton, Jean-Pascal
    Rouby, Franck
    Atzenhoffer, Martine
    Lafay-Chebassier, Claire
    Perault-Pochat, Marie Christine
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (03) : 397 - 407
  • [7] Drug-induced gingival bleeding: a case/non-case study from the French Pharmacovigilance Database
    Bondon-Guitton, E.
    Mourgues, T.
    Rousseau, V.
    Jean-Pastor, M. J.
    Cottin, J.
    Drablier, G.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 3 - 4
  • [8] Drug-induced retroperitoneal fibrosis: a case/non-case study in the French PharmacoVigilance Database
    Brasselet, Diana
    Chouchana, Laurent
    Vial, Thierry
    Damin-Pernik, Marlene
    Lebrun-Vignes, Benedicte
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (07) : 903 - 913
  • [9] Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database
    Trenque, T
    Piednoir, D
    Frances, C
    Millart, H
    Germain, ML
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (04) : 281 - 283
  • [10] Statins and Erectile DysfunctionResults of a Case/Non-Case Study using the French Pharmacovigilance System Database
    Catherine Do
    Eric Huyghe
    Maryse Lapeyre-Mestre
    Jean Louis Montastruc
    Haleh Bagheri
    Drug Safety, 2009, 32 : 591 - 597